Our study demonstrates that a low EMX2 expression level is an independent prognostic factor and correlates with dismal prognosis, decreased overall survival and the development of metastatic disease in stage III colorectal cancer patients. This evidence concerns the gene EMX2 and metastatic neoplasm.